newsfilter
← Latest News
GlobeNewswire·

Genmab Portfolio Prioritization Update

Company Announcement Genmab to discontinue clinical development of acasunlimab following a portfolio reviewDecision reflects prioritization of higher‑impact opportunities across Genmab's late‑stage pipeline and